Can you drive an entire program?

Simply, Yes.

It's our specialty. We have the experience, operational capacity, and global resources to effectively support and drive your program in order to meet your desired milestones.

Charles River is willing and able to take on stand-alone studies or transactional accounts, but our real value lies in our unique ability to shepherd clients from bench to bedside, offering a portfolio of services that span the drug development continuum from basic research through the support of manufactured products. Seasoned advisors and scientists who’ve been in your shoes are with you every step of the way, helping you to see around the corner for more efficient, successful programs.

With access to one of the industry’s most comprehensive portfolios – from early discovery to market support – we are uniquely qualified to map and drive your journey though product development. When you partner with Charles River you gain the confidence of working with a company who has supported the development of 85% of the drugs approved by the FDA, additional therapies with other global regulatory agencies, and products in the chemical and agrochemical space around the globe in the last year alone.

...I believe that we'll be able to help move these companies' drugs to the clinic faster.

~85%
of drugs approved by the FDA in 2018 were supported by Charles River
88%
of approved oncology therapies
161
IND Programs submitted to agency in 2019
70+
years of experience
802
IND-enabling programs supported year to date
31,722
reports delivered in 2019
3,368
SEND datasets delivered in the last 12 months
Start the Conversation